hypercoagulability and hyperfibrinolysis. The D-dimer assay is a sensitive, but non-specific indicator that has been widely used by clinicians to detect deep vein thrombosis (DVT) or pulmonary embolism (PE), and to diagnose or monitor disseminated intravascular coagulation (DIC) or serve as an effective indicator of thrombolytic or anticoagulant therapy. 3 Many different D-dimer analyses have been developed, which differ in the D-dimer epitope targeted by the antibody, method of capture and detection, instrumentation required, and calibration standard. It has been reported that there are 20 different monoclonal antibodies used by 30 different D-dimer assays. 4 In general, these assays use homogeneous sandwiches of monoclonal antibodies to detect specific epitopes on cross-linked D-dimer fragments, including methods based on hemagglutination, fluorescence, chemiluminescence, or other techniques. 5 In clinical laboratories, automated multi-function instruments generally rely on various test methods, such as enzyme immunoassays, immunofiltration, and immunochromatography. However, immunoassays are inherently susceptible to heterophilic antibodies, that is, interference with endogenous antibodies that measure the antibody, and the consequences of this interference can be devastating ( Figure 2 ). 6 There have been many reports of heterophilic antibodies affecting assay results in various tests, such as human chorionic gonadotropin, cardiac troponin I, and prostate-specific antigen. [7] [8] [9] Various types of interfering antibodies affect about 0.05%-0.5% of immunoassays 10 and in 8 automated tumor marker immunoassays, the prevalence of heterophilic antibodies was 0.2%-3.7%. 11 In daily clinical work, acquisition of D-dimer results inconsistent with clinical symptoms and imaging data is not unique, and we have encountered two such patients whose FDP values were normal, but D-dimer levels were immunoturbidimetric immunoassay) for D-dimer values, under normal quality control conditions, and the operation strictly in accordance with the instructions.
| Comparative test

| Dilution test
Serum samples were serially diluted by twofold multiples (2, 4, 8, 16 , and 32 times) and measured using the same methods and instruments as the initial measurements (commercial latex-enhanced immunoturbidimetric assay, Siemens AG). Then, the dilution ratio was used as the abscissa, and the D-dimer result as the ordinate to draw a linear plot.
| Heterophilic antibody blocking reagent (HBR)
Samples were treated with a heterophilic blocking reagent (HBR, Scantibodies Laboratory Inc, USA) following the instructions. Briefly, the HBR was immediately thawed in a water bath and gently shaken upright then added directly to the experimental sample. After incubation at the temperature required by the instructions, a D-dimer assay is performed. The control group was identical to the sample except that no HBR was added.
| Systematic review and analysis
We systematically searched PubMed, Web of Science, and Scopus for articles about cases on heterophilic antibodies or other factors influencing D-dimers and D-dimer assays, then performed a systematic analysis. The following keywords were used: "human anti-mouse antibody" or "HAMA" or "heterophile" or "heterophilic" in combination with "D-dimer". In addition, other relevant literature references were reviewed. All articles identified according to these search criteria were evaluated by two authors (Wu Y and Zhang XY).
| RE SULTS
| Comparative Test
The results measured by another instrument and testing method (HemosIL D-dimer HS for ACL TOP, Latex-enhanced immunoturbidimetric immunoassay) were within the normal reference range (Table 1) .
| Dilution Test
From Figure 3 there was no linear relationship between the D-dimer value and the dilution factor. The D-dimer value decreased after dilution and then fluctuated above the reference value.
| Heterophilic antibody blocking reagent (HBR)
The 
| Systematic review and analysis
Articles that met the conditions were collected and summarized, including six articles, of which four were in English, one in French, and one in Chinese. According to literature data, there were 66.7% (4/6) ref-
erences showed the interference were heterophilic antibody. (Table 2 ).
| D ISCUSS I ON
Heterophilic antibody is a kind of multispecific immunoglobulin produced when a known or unknown antigenic substance stimulates the human body, it has sufficient titer and can bind weakly to immunoglobulins of multiple species. The prevalence of heterophilic antibodies in the general population is 0.17%-40%. From a review and analysis of prior literature ( 22 and the "standardization" of the specificity of the assay antibodies may be considered to be a first and most important step. 2 Before the D-dimer assay standardization, when results are suspicious, use a combination of instrumental methods when measure, deal with heterophilic antibody blockers in necessity and connect with the clinical performance and imaging data can rule out most of the interference.
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